Acta Ortop Mex. 2023 Jan-Feb;37(1):30-35.
INTRODUCTION: osteoarthritis is one of the most prevalent chronic diseases in the world and is defined as the gradual loss of cartilage in the joints, mainly that of the knee. It is considered a cause of disability in older adults and is characterized by pain, stiffness and loss of mobility.
MATERIAL AND METHODS: observational study to evaluate the effect of the combination of non-hydrolyzed type II native collagen (CII-NH), omega-3 (Om-3) and astaxanthin (AX), in a population of 182 patients with knee osteoarthritis grade I/II. Measurements of thigh circumference, arcs of movement and pain were obtained through international scales such as the visual analogue pain scale (VAS), the Lequesne index and the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) scale. Medical check-ups were performed every 30 days for three months. The Statgraphics software (Statgraphics Technologies, Virginia) was used, the evaluation of the variables and the statistical significance were determined by t Student test and the results are shown as a mean.
RESULTS: it was shown that daily consumption increases mobility, decreases knee pain and inflammation in patients within three months. Additionally, there was a reduction in the consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) by the study subjects.
CONCLUSION: the fixed combination of non-hydrolyzed type II collagen, omega-3 and astaxanthin, generates, in the short term, a decrease in inflammation and stiffness in patients with osteoarthritis.